CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
PF-06741086 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02974855
NCT02974855Phase 2Completed
CompareCT.gov

A MULTICENTER, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA

Pfizer·interventional·Posted Nov 29, 2016·Updated Dec 4, 2019

In Brief

A Phase 2 clinical trial evaluating PF-06741086 for Hemophilia A or B. Completed, enrolled 27 participants across 10 sites in 6 countries.

Detailed Summary

This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia A or B
CountriesChile, Croatia, Poland, South Africa, Switzerland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 29, 2016
Enrollment StartMar 8, 2017
Primary CompletionDec 3, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.6 years ago

Interventions

PF-06741086biological

PF-06741086 subcutaneous (SC) injection

PF-06741086biological

PF-06741086 SC injection

PF-06741086biological

PF-06741086 SC injection

PF-06741086biological

PF-06741086 SC injection